Clinical Scorecard: Is Routine Antibiotic Prophylaxis Needed for Laparoscopic Adnexal Surgery? A Multicenter Cohort Study
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Is Routine Antibiotic Prophylaxis Needed for Laparoscopic Adnexal Surgery? A Multicenter Cohort Study
Key Mechanisms
The study compares pre-incision cefazolin with no prophylactic antibiotics and evaluates 30-day SSI incidence after laparoscopic adnexal surgery.
Target Population
Patients included in the source article's study population.
Care Setting
Care setting described in the source article.
Key Highlights
This multicenter retrospective cohort compared 30-day SSI incidence in patients given pre-incision cefazolin with incidence in patients given no prophylactic antibiotics.
Eligible procedures included laparoscopic adnexectomy, ovarian cystectomy, and salpingectomy for benign disease.
SSI was classified as superficial incisional, deep incisional, or organ/space pelvic infection using CDC criteria.
The study also assessed associations between SSI and selected patient and perioperative factors.
The supplied article text does not include study results, so comparative effects and associated risk factors cannot be reported.
Guideline-Based Recommendations
Diagnosis
The study defined its primary outcome as SSI within 30 days after surgery, categorized by CDC criteria as superficial incisional, deep incisional, or organ/space pelvic infection.
Management
The Japanese Society of Chemotherapy advises cefazolin before laparoscopic adnexal surgery.
ACOG and SOGC advise against routine prophylaxis for class I clean laparoscopic procedures without gastrointestinal or genitourinary tract entry, citing insufficient evidence of benefit.
Monitoring & Follow-up
The study assessed SSI incidence within 30 days after surgery as its primary outcome.
The study assessed age, BMI, diabetes, endometriosis, prior abdominal surgery, uterine manipulator use, operative time, and blood loss as factors associated with SSI.
Risks
The article identifies obesity, diabetes mellitus, smoking, and immunocompromised status as recognized patient-related SSI risk factors.
The article notes concerns about excessive prophylactic antibiotic use, including antibiotic resistance, allergic reactions, and disturbances to normal microbiomes.
Patient & Prescribing Data
Consecutive patients undergoing laparoscopic adnexal surgery for benign indications were eligible. Exclusions were adnexal abscess or pelvic inflammatory disease, conversion to laparotomy, tissue retrieval through a transvaginal or small-laparotomy incision, concurrent hysteroscopy, or prophylaxis other than cefazolin.
At six hospitals, protocols specified intravenous cefazolin 1–2 g within 60 minutes before skin incision; one hospital did not routinely administer prophylactic antibiotics. The supplied text does not report comparative SSI results.
Clinical Best Practices
The article describes differing recommendations: the Japanese Society of Chemotherapy advises cefazolin, whereas ACOG and SOGC advise against routine prophylaxis for class I clean laparoscopic procedures without gastrointestinal or genitourinary tract entry.
Antibiotic use was determined by participating facility policy in this retrospective cohort.
The supplied text does not state that smoking, immunocompromised status, or nutritional status were uniformly documented; remove this claim unless supported by additional source text.
